Your browser doesn't support javascript.
Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.
García-Grimshaw, Miguel; Michel-Chávez, Anaclara; Vera-Zertuche, Juan Mauricio; Galnares-Olalde, Javier Andrés; Hernández-Vanegas, Laura E; Figueroa-Cucurachi, Melissa; Paredes-Ceballos, Orlando; Reyes-Terán, Gustavo; Carbajal-Sandoval, Guillermo; Ceballos-Liceaga, Santa Elizabeth; Arauz, Antonio; Valdés-Ferrer, Sergio Iván.
  • García-Grimshaw M; Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Michel-Chávez A; Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Vera-Zertuche JM; Department of Endocrinology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Galnares-Olalde JA; Department of Neurology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
  • Hernández-Vanegas LE; Department of Neurology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
  • Figueroa-Cucurachi M; Hospital Faro del Mayab, Merida, Yucatán, Mexico.
  • Paredes-Ceballos O; Hospital Faro del Mayab, Merida, Yucatán, Mexico.
  • Reyes-Terán G; Secretaría de Salud, Gobierno de México, Mexico.
  • Carbajal-Sandoval G; Secretaría de Salud, Gobierno de México, Mexico.
  • Ceballos-Liceaga SE; Secretaría de Salud, Gobierno de México, Mexico.
  • Arauz A; Department of Neurology, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.
  • Valdés-Ferrer SI; Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Feinstein Institutes for Medical Research, Ma
Clin Immunol ; 230: 108818, 2021 09.
Article in English | MEDLINE | ID: covidwho-1531118
ABSTRACT
Vaccines are the most effective strategy to mitigate the global impact of COVID-19. However, vaccine hesitancy is common, particularly among minorities. Guillain-Barré syndrome (GBS) is the most common autoimmune illness of the peripheral nervous system, occurring at an incidence of 1.1/100,000 worldwide. A causal link between mRNA vaccines and GBS has not been previously evaluated. We analyzed a cohort of 3,890,250 Hispanic/Latinx recipients of the BNT162b2 mRNA vaccine (613,780 of whom had already received both doses) for incident GBS occurring within 30 days from vaccine administration. Seven cases of GBS were detected among first-dose recipients, for an observed incidence of 0.18/100,000 administered doses during the prespecified timeframe of 30 days. No cases were reported after second-dose administration. Our data suggest that, among recipients of the BNT162b2 mRNA vaccine, GBS may occur at the expected community-based rate; however, this should be taken with caution as the current incidence of GBS among the unvaccinated population against COVID-19 is still undetermined. We hope that this preliminary data will increase the public perception of safety toward mRNA-based vaccines and reduce vaccine hesitancy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Guillain-Barre Syndrome / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: J.clim.2021.108818

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Guillain-Barre Syndrome / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: J.clim.2021.108818